Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-ART-1920
J Med Chem. May 19, 2005; 48 (10): 3474-7.

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.

Coe JW , Brooks PR , Vetelino MG , Wirtz MC , Arnold EP , Huang J , Sands SB , Davis TI , Lebel LA , Fox CB , Shrikhande A , Heym JH , Schaeffer E , Rollema H , Lu Y , Mansbach RS , Chambers LK , Rovetti CC , Schulz DW , Tingley FD , O'Neill BT .


Abstract
Herein we describe a novel series of compounds from which varenicline (1, 6,7,8,9-tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine) has been identified for smoking cessation. Neuronal nicotinic acetylcholine receptors (nAChRs) mediate the dependence-producing effects of nicotine. We have pursued alpha4beta2 nicotinic receptor partial agonists to inhibit dopaminergic activation produced by smoking while simultaneously providing relief from the craving and withdrawal syndrome that accompanies cessation attempts. Varenicline displays high alpha4beta2 nAChR affinity and the desired in vivo dopaminergic profile.

PubMed ID: 15887955
Article link: J Med Chem.

Genes referenced:
Antibodies referenced:

My Xenbase: [ Log-in / Register ]
version: [3.2.2]


Major funding for Xenbase is provided by the National Institute of Child Health and Human Development, grant P41 HD064556